Catalyst Pharma Acquires Firdapse Rights
Ticker: CPRX · Form: 8-K · Filed: Jul 26, 2024 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Jul 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, drug-rights, rare-disease
TL;DR
Catalyst Pharma buys Firdapse US rights from Adare Pharma for $150M, closing Q4 2024.
AI Summary
Catalyst Pharmaceuticals, Inc. announced on July 24, 2024, that it has entered into a definitive agreement to acquire the U.S. rights to Firdapse from Adare Pharma Solutions. The acquisition is expected to close in the fourth quarter of 2024 and will be funded through a combination of cash on hand and a new credit facility. This move aims to strengthen Catalyst's rare disease portfolio.
Why It Matters
This acquisition allows Catalyst Pharmaceuticals to expand its rare disease drug portfolio by gaining control of Firdapse in the U.S., potentially increasing its market presence and revenue streams in this specialized area.
Risk Assessment
Risk Level: medium — The acquisition involves significant financial commitment and integration risks, and the success of Firdapse post-acquisition is subject to market dynamics and regulatory factors.
Key Numbers
- $150 million — Acquisition Cost (Catalyst Pharmaceuticals is acquiring the U.S. rights to Firdapse for this amount.)
- Q4 2024 — Expected Closing (The acquisition is anticipated to be completed by the end of the fourth quarter of 2024.)
Key Players & Entities
- Catalyst Pharmaceuticals, Inc. (company) — Registrant
- Adare Pharma Solutions (company) — Seller of Firdapse U.S. rights
- Firdapse (drug) — Acquired product
- July 24, 2024 (date) — Date of report and earliest event
- Q4 2024 (date) — Expected closing quarter of acquisition
- $150 million (dollar_amount) — Purchase price for Firdapse U.S. rights
FAQ
What specific rare disease does Firdapse treat?
The filing does not specify the exact rare disease Firdapse treats, but it is acquired by Catalyst Pharmaceuticals, Inc. which focuses on rare diseases.
What is the total purchase price for the U.S. rights to Firdapse?
Catalyst Pharmaceuticals, Inc. has entered into a definitive agreement to acquire the U.S. rights to Firdapse for $150 million.
When is the acquisition of Firdapse expected to close?
The acquisition is expected to close in the fourth quarter of 2024.
How will Catalyst Pharmaceuticals fund the acquisition?
The acquisition will be funded through a combination of cash on hand and a new credit facility.
Who is the seller of the U.S. rights to Firdapse?
The U.S. rights to Firdapse are being acquired from Adare Pharma Solutions.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-07-26 16:30:59
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d810788d8k.htm (8-K) — 27KB
- d810788dex991.htm (EX-99.1) — 14KB
- 0001193125-24-186261.txt ( ) — 166KB
- cprx-20240724.xsd (EX-101.SCH) — 3KB
- cprx-20240724_lab.xml (EX-101.LAB) — 18KB
- cprx-20240724_pre.xml (EX-101.PRE) — 11KB
- d810788d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on July 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer Dated: July 26, 2024 3